Politics About the Author Reprints Log In | Learn More What is it? GET STARTED ‘We have to get back on track’: Democrats lose patience with Trump on drug pricing [email protected] What’s included? Erin Mershon Senior News Editor Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED President Trump spent the last several weeks blasting Democrats for refusing to work with Republicans on health care. Now, two of the Democrats who have shown the most willingness to work with him on one specific health issue ― drug pricing ― are blasting him back.Reps. Peter Welch of Vermont and Elijah Cummings of Maryland made headlines when they agreed to meet Trump at the White House in March to discuss efforts to bring down drug prices, even as many of their colleagues worked to distance themselves from the president. The pair came away from that meeting optimistic about Trump’s willingness to press for relatively liberal changes, like allowing the importation of drugs from Canada or letting Medicare negotiate drug prices. Alex Hogan/STAT By Erin Mershon June 23, 2017 Reprints Tags Congressdrug pricingpharmaceuticalspolicySTAT+TrumpWhite House @eemershon STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What is it? Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED They get to name genes ‘happyhour’ and ‘Pavarotti.’ Fly researchers have all the fun GET STARTED In the Lab Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Log In | Learn More STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? By Megha Satyanarayana Oct. 25, 2017 Reprints Tags researchSTAT+ “Do you know what unc-64 stands for?”This is actually a reasonable question, coming from a “fly person” to a “worm person.” Dominic Hart/NASA
About the Author Reprints @Pharmalot Alden Pellett/AP Ed Silverman Seeking a way to alleviate high drug prices, a Utah lawmaker hopes to introduce a bill that would allow the state to import prescription medicines from Canada, a move that is likely to accelerate a fierce debate over drug costs and patient safety.Over the next several weeks, Rep. Norman Thurston, a Republican, plans to submit legislation to authorize state officials to designate an existing pharmaceutical wholesaler to purchase prescription drugs from a wholesaler in Canada. His hope is that retail pharmacies based in Utah would then be able to buy and sell medicines at lower prices. What is it? Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. What’s included? GET STARTED Tags drug pricingpharmaceuticalsSTAT+ Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED Log In | Learn More Pharmalot By Ed Silverman Oct. 26, 2017 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. [email protected] Utah lawmaker is working on a plan to import medicines from Canada Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Women in the study had a CellSearch test five years on average after their cancer was found and treated.Among those with estrogen-fueled disease, 5 percent had cancer cells in the blood test, and they turned out to have a 22-fold higher risk of recurrence within roughly two years compared to women whose blood test was negative.About 65 percent of women with hormone-positive disease and a positive blood test did not have a new breast cancer within two years, but that doesn’t mean the blood test gave a false alarm, Sparano said.“We haven’t followed the patients long enough” — it could be that more tumors become evident with more time, he said.The blood test seemed to do a good job of identifying which of these hormone-positive patients were at low risk of recurrence, suggesting that women who test negative may be able to forgo an additional five years of hormone-blocking medicines.The test did not predict recurrence risk in the rest of the women in the study, whose tumors were not fueled by estrogen. They have a lower risk of recurrence after five years to start with.The study was funded by the Breast Cancer Research Foundation, Susan G. Komen Foundation and the National Cancer Institute.— Marilynn Marchione Can a ‘liquid biopsy’ detect cancer and save lives? Related: On the other hand, “if you had a negative test, there was a 98 percent chance you would not have a recurrence in the next two years” and perhaps could skip further treatment, he said.Sparano led the study and gave results Friday at the San Antonio Breast Cancer Symposium.advertisement A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.It was the largest experiment so far to use these tests, called liquid biopsies , for breast cancer. Results suggest they someday may help reveal which women need longer preventive therapy and which ones can be spared it.“It could be providing an early warning sign” for some women that cancer is returning, said Dr. Joseph Sparano of Montefiore Einstein Center for Cancer Care in New York.advertisement A patient has her blood drawn for a liquid biopsy. Jacqueline Larma/AP Related: HealthBlood test may help predict which breast cancers will recur The test — CellSearch, sold by Menarini-Silicon Biosystems — looks for stray cancer cells in the blood. By Associated Press Dec. 8, 2017 Reprints Newer birth control pills still modestly raise risk of breast cancer Breast cancer survivors may be tempted to rush out and get it, but doctors say it’s too soon for that. Although it’s been used for about a decade to monitor certain patients with advanced cancer during treatment, its value for helping to predict breast cancer relapse risk is not well established, and insurers won’t pay the $600 to $900 tab.The new study should spur more research on this right away, said Dr. Massimo Cristofanilli, a breast cancer specialist at Northwestern University in Chicago who has used these tests and consults for another company developing one.“Clearly, to me, we have to do something” now that this study suggests a wider role for them, he said.It involved 547 women in long-term follow-up from an earlier cancer drug study. Two-thirds of them had cancers fueled by estrogen, and in most cases it had spread to lymph nodes but not more widely.All had surgery and chemotherapy followed by hormone-blocking medicines for five years. Guidelines now recommend considering hormone blockers for up to 10 years, but they have side effects and their benefit beyond five years is fairly small. So finding a way to tell who really needs that would be a big help. About the Author Reprints Associated Press
WASHINGTON — For the first time in years, the medical device tax will take effect Jan. 1, after Congress left town without delivering on a long-promised delay or repeal. But opponents of the tax, both in industry and on Capitol Hill, aren’t giving up yet: They’re scrambling to find another solution that could offer some relief at the start of the new year.Already they’ve secured commitments from congressional leaders that they will delay or repeal the 2.3 percent excise tax early in 2018. And now some lobbyists and lawmakers are working with the Treasury Department in hopes that the Trump administration will waive the penalties associated with problematic compliance in the early weeks of the year, before Congress might make good on its effort to address the tax. That will help companies whose accounting and reporting systems might not be ready for the Jan. 1 start date, an industry official said. By Erin Mershon Dec. 22, 2017 Reprints Tags policy GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @eemershon Politics What’s included? What is it? About the Author Reprints Rep. Erik Paulsen (R-Minn.), a longtime opponent of the medical device tax Alex Wong/Getty Images Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Erin Mershon Senior News Editor Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED [email protected] Medical device tax comes back Jan. 1, but opponents trying to ease its effects Log In | Learn More
A CDC researcher works in a BSL4 laboratory, where the most dangerous pathogens are studied. CDC By Helen Branswell Feb. 23, 2018 Reprints About the Author Reprints Senior Writer, Infectious Disease Helen covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. The Centers for Disease Control and Prevention is asking Congress for money for a new building to house the laboratories that work on the deadliest pathogens known to humankind. The existing building, which went into service in 2005, will need to be replaced by 2023 or so to avoid major disruptions in the work, senior agency staff told STAT.“The concerns are that the facility we’ve been in now is beginning to show signs of age,” said Dr. Inger Damon, head of the division of high consequence pathogens and pathology. That division works on viruses like smallpox and Ebola, which can only be studied in laboratories of the highest biosafety and biosecurity ratings, BSL4.The request, which is currently in the proposed budget for fiscal year 2018, is for $350 million. But more will be needed later; the new high containment continuity laboratory, as it is called, would be built on the site of one of only a few parking facilities on the CDC’s main campus.advertisement In the LabCDC requests funds to build new maximum-security laboratory Trending Now: Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson (The main campus is in a part of the city not served by the Atlanta subway system; parking on the site is already inadequate for the number of people who work there.)The existing facility contains a number of BSL4 labs and labs that are one step down the biosafety and biosecurity ladder, BSL 3 enhanced. That’s where research on dangerous avian influenza viruses like H5N1 and H7N9 is conducted.advertisement Buildings that house these types of labs simply require a lot of maintenance, explained Dr. Dan Jernigan, head of the CDC’s influenza branch.“We’re just faced with the realities of what it takes to maintain something as complex as the high containment lab,” he said.These types of buildings incorporate complicated air filtration and other systems designed to allow the researchers to work safely as well as to ensure that the bad bugs they contain stay on the inside.The CDC’s goal is to have the new facility built in time to ensure the transition from the current labs to the new ones is seamless, Damon said. It will take a number of years to build the new facility and have it certified for select-agent research.“We’ve always tried to maintain that continuity. I think there’s just too much that’s unpredictable,” Damon said. “When you need that facility … you want to have it available. You don’t know when the next SARS is going to happen, or the next large Ebola outbreak.” Helen Branswell @HelenBranswell